This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Ovarian cancer	MicroRNA-155 (miR-155)	<p>Studies in mice suggest anti-CD40 antibodies plus nanoparticles carrying pre-miR-155 could be used to treat ovarian cancer. In mice bearing ovarian tumors, anti-CD40 antibodies plus nanoparticles carrying pre-miR-155 led to increased tumor antigen-specific T cell responses and overall survival compared with anti-CD40 antibodies plus nanoparticles carrying control miR-155. Next steps include moving the strategy into clinical trials with ovarian cancer patients.</p> <p><i>SciBX</i> 5(8); doi:10.1038/scibx.2012.202 Published online Feb. 23, 2012</p>	Unpatented; licensing status not applicable	<p>Cubillos-Ruiz, J.R. <i>et al. Cancer Res.</i>; published online Feb. 3, 2012; doi:10.1158/0008-5472.CAN-11-3160 Contact: Jose R. Conejo-Garcia, The Wistar Institute, Philadelphia, Pa. e-mail: jrconejo@wistar.org</p>